Musica Universalis · Health · The Honest Reckoning
The Pharmacopoeia
Drugs, healing & the suppressed science · where medicine meets power
Every molecule that changes the mind or body began in nature, or mimics what nature built. The same compounds governments schedule as dangerous have, in many cases, been used safely for thousands of years. What follows is the honest account, the costs, the timelines, the suppression, and the quiet revolution happening in clinics, forests, and therapist offices around the world.
Section I
What Is a Drug, Actually?
A drug is any molecule that binds to a receptor and changes something. Your body runs on endogenous drugs, dopamine, serotonin, endorphins, cortisol, oxytocin, anandamide (your internal cannabis). The word "drug" carries moral weight it doesn't scientifically deserve. Caffeine is a drug. Alcohol is a drug. Penicillin is a drug. The distinction between "medicine" and "drug" is almost entirely political.
Every neurotransmitter you have was shaped by millions of years of evolution, and almost every psychoactive compound known to medicine works because it mimics or modulates those same ancient systems. Opioids work because your brain has opioid receptors. Those receptors didn't evolve waiting for pharmaceutical companies, they evolved to respond to endorphins. Psilocybin works because your brain has serotonin (5-HT2A) receptors. THC works because your brain has endocannabinoid receptors.
The receptor came first. The plant molecule found it second. The pharmaceutical came third.
"The brain doesn't have opioid receptors because opium exists. Opium works because the brain was already talking to itself in the same chemical language."
Basic neuropharmacology · the endogenous ligand principle
Section II
Why Drug Development Takes So Long (And Who Benefits From That)
The average time from molecule discovery to approved drug: 10–15 years. Average cost claimed by the pharmaceutical industry: $2.6 billion. The real cost of manufacturing most small-molecule drugs once approved: often $1–$10 per dose. Understanding why those numbers are so different requires understanding who controls the pipeline.
Discovery
Years 1–4 · Mostly taxpayer-funded at universities
Preclinical
Years 3–6 · Safety & pharmacology in animals
Phase I
Years 6–8 · First human dosing, safety
Phase II
Years 7–10 · Efficacy signal, dose-finding
Phase III
Years 9–13 · This is where $1B+ goes. 3–5 large RCTs
FDA Review
Years 12–14 · Regulatory submission & review
Phase IV / Market
Year 14+ · Post-market safety, label expansion
Phase III trials are the main cost driver, but they are also the main profit protection mechanism. Because the same trials that prove efficacy are impossible for competitors to replicate for 20 years (patent life), the company that survives Phase III has a monopoly. The lengthy process isn't just bureaucracy. It's a moat.
The $2.6 billion figure (from Tufts Center for the Study of Drug Development, partly industry-funded) includes opportunity cost, the money the company could theoretically have earned if they'd invested elsewhere. It also averages in the cost of failed drugs. The real out-of-pocket cost for Phase III trials is typically $300–$700 million. Still substantial, but the figure used in pricing justifications is the inflated one.
10–15Years to approvalAverage discovery-to-market timeline for a new drug
$2.6BIndustry-claimed costIncludes all failed drugs, opportunity cost. Tufts/industry estimate.
$1–10Manufacturing cost/doseMost small molecules. Biologics are more. The markup can be 1,000,000%.
~10%Approval rateOnly ~10% of drugs entering Phase I reach approval
20 yrPatent exclusivityAfter which generics can enter. Many companies game this with minor reformulations.
~50%Publicly fundedMost foundational research is NIH-funded. Industry captures the patent.
The Uncomfortable Truth
Most of the basic science behind approved drugs was funded by taxpayers through the NIH, NSF, and public universities. Industry takes those discoveries, funds the expensive regulatory process, and claims a 20-year monopoly on pricing. The research was socialized. The profit is privatized. A 2018 analysis found that all 210 drugs approved by the FDA between 2010–2016 had received NIH funding in their research history, totaling $100 billion in public investment.
Section III
Where Do Drugs Come From? Are the Most Powerful Natural or Synthetic?
Most people assume powerful drugs are laboratory inventions. The reality is inverted. The most potent and most medically significant drugs are almost all derived from, or inspired by, natural compounds. Nature spent 500 million years doing medicinal chemistry. We have been studying it for 200 years.
The reason: plants, fungi, and bacteria evolved these molecules specifically to interact with animal nervous systems, to repel predators, attract pollinators, kill competing microorganisms. When a plant produces a molecule that binds human receptors, it's because it was targeting the same ancient receptor system in the insects or mammals that were eating it. We are, neurologically, much older than we think.
Morphine / Opioids
Papaver somniferum, the opium poppy. Used for 5,000+ years. Template for all opioid drugs including fentanyl, oxycodone.
Extreme potency
Psilocybin
80+ species of Psilocybe fungi. Indigenous use for millennia in Mesoamerica, Siberia, possibly Europe. Most promising antidepressant of the 21st century.
Transformative potency
Mescaline / Peyote
Lophophora williamsii (peyote cactus). Native American ceremonial use 5,000+ years. Strong 5-HT2A agonist.
High potency
Cocaine / Lidocaine
Erythroxylum coca. Chewed by Andean peoples for altitude and energy. Template for all local anesthetics used in surgery today.
Extreme potency
DMT / Ayahuasca
Dozens of plants including Psychotria viridis. Possibly endogenously produced in human pineal tissue. Pan-Amazonian ceremonial use 2,000+ years.
Extreme potency
Cannabis / THC
Cannabis sativa/indica. Used medicinally in China as early as 2700 BCE. Now proven for pain, nausea, epilepsy, MS spasticity.
High potency
Aspirin
Salicylic acid from willow bark, used in ancient Egypt, Greece, and by indigenous North Americans. Synthesized 1897 but nature did it first.
Moderate potency
Penicillin
Penicillium mold. Discovered 1928 (Fleming). The mold had been making it for millions of years to kill bacteria.
Extreme (saved ~200M lives)
Ibogaine
Tabernanthe iboga root bark. West African Bwiti ceremonies. Single dose interrupts opioid/cocaine ⚐ CF A: addiction as comma accumulation: each use creates a slightly larger gap between the medicated state and the sober state, requiring more to close the same distance addiction in 60–80% of cases in clinical settings.
Extreme potency
LSD (Lysergic acid diethylamide)
Semi-synthetic, derived from ergot fungus alkaloids (Claviceps purpurea). Synthesized by Albert Hofmann in 1938. One of the most potent serotonergic compounds known.
Extreme potency
MDMA (Ecstasy)
Synthesized 1912 by Merck. Re-discovered by Alexander Shulgin in 1976. Safrole precursor comes from sassafras. FDA Breakthrough Therapy for PTSD since 2017.
High potency
Fentanyl
Fully synthetic opioid. 100× more potent than morphine. The template was natural (morphine). The power was engineered. Now responsible for >70,000 US overdose deaths/year.
Extreme / dangerous
Ketamine
Synthesized 1962 as anesthetic. Now first FDA-approved rapid-acting antidepressant (as esketamine/Spravato). Works in hours vs weeks for SSRIs.
High potency
SSRIs (Prozac, Zoloft)
Fully synthetic. Designed to prolong serotonin in the synapse. Effective for ~40–60% of patients with major depression. Often first-line treatment despite limited effect size in mild depression.
Moderate potency
Metformin
Semi-synthetic, derived from Galega officinalis (French lilac). First-line Type 2 diabetes drug. One of the most prescribed drugs on Earth. Costs pennies to manufacture.
High utility
2C-B / Novel Psychedelics
Synthesized by Alexander Shulgin from phenethylamine template found in mescaline. Published in PiHKAL (1991). Hundreds of novel compounds systematically synthesized by one chemist working from a natural scaffold.
High potency
Conclusion
The most potent substances known, opioids, ⚐ CF Q: Psychedelics appear to temporarily dissolve the default mode network's self-model. Is the therapeutic effect a comma reset: disrupting a phase-locked pathological state long enough for a new phase relationship to establish? psychedelics, stimulants, antibiotics, all derive from or were designed around natural templates. Nature is still the best medicinal chemist. Synthetic chemistry amplified power and bioavailability; it rarely discovered entirely novel mechanisms. The most dangerous drugs (fentanyl, synthetic opioids) are the ones most engineered away from nature's original formulation.
Section IV
Why Research Was Halted: The Controlled Substances Act & the War on Science
In the early 1960s, psychedelic research was one of the most exciting areas in psychiatry. The Harvard Psilocybin Project (1960–1963) produced promising results for alcoholism, criminality, and end-of-life anxiety. LSD research had published over 1,000 papers and was showing 50–90% abstinence rates in alcoholism trials. MDMA was being used by thousands of therapists in couples counseling.
Then in 1970, the Controlled Substances Act classified LSD, psilocybin, mescaline, and dozens of other psychedelics as Schedule I, meaning: no accepted medical use, high abuse potential, unsafe even under medical supervision. Research effectively stopped for 25 years. Access to Schedule I substances for research requires DEA approval, DEA-registered labs, institutional review boards, and FDA IND applications, layers of bureaucracy that make research nearly impossible.
John Ehrlichman, Nixon's domestic policy chief, admitted in 2016 that the Controlled Substances Act was explicitly designed to criminalize the anti-war left and Black Americans: "We knew we couldn't make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities."
1970
Controlled Substances Act (CSA)
LSD, psilocybin, MDMA, mescaline, and cannabis placed in Schedule I. Despite MDMA not yet existing as a recreational drug and psilocybin showing clinical promise, the classification blocked research for decades. The scheduling was political, not medical, it came from the Nixon administration, not from scientific review.
1972–1994
25 Years of Suppression
Virtually no human psychedelic research conducted in the US or UK. Researchers who continued (like Rick Doblin of MAPS) had to work in other countries or through years of bureaucratic obstruction. Careers were ended. Labs were defunded. The institutional memory of clinical protocols was largely lost.
1986
MDMA Emergency Scheduling
The DEA emergency-scheduled MDMA despite its creator Alexander Shulgin, therapist Leo Zeff, and clinical researcher George Greer all testifying to its safety and therapeutic value. The DEA's own Administrative Law Judge Francis Young recommended Schedule III. The DEA overruled him. The legal battle lasted until 1988; the drug was permanently placed in Schedule I.
2000–2010
The Psychedelic Renaissance Begins
The FDA began approving limited research. Johns Hopkins, NYU, and Imperial College London started psilocybin trials. Results were striking enough that the narrative could no longer be fully suppressed. The question became: why was this suppressed for 30 years when the initial 1960s results were already this strong?
2017–2023
FDA Breakthrough Therapy Designations
MDMA for PTSD (2017) and psilocybin for treatment-resistant depression (2018, 2019) receive FDA Breakthrough Therapy designation, the highest priority rating, acknowledging they show "substantial improvement over available therapy." The suppressed science was coming back, with decades of lost time.
The Cost of Suppression
25 years of halted research on substances that show 60–80% remission rates for treatment-resistant depression, PTSD, addiction, and end-of-life anxiety. During those same 25 years, SSRI antidepressants, with ~40% response rates and significant side effects, became a $15 billion/year industry. The question of cui bono (who benefits?) from prolonged Schedule I status is not a conspiracy theory. It is a straightforward economic analysis.
Section V
The Truth About Microdosing
Microdosing, taking sub-perceptual doses of psychedelics (typically psilocybin or LSD) every few days, became a Silicon Valley phenomenon around 2016. The claims were extraordinary: improved creativity, emotional regulation, focus, energy, reduced anxiety and depression with none of the "trip." The actual science is more nuanced and more interesting.
🔬
Microdose
1–3% full dose
Sub-perceptual. No visual effects. Taken every 3 days (Fadiman Protocol). Claimed: focus, reduced depression, creativity. Some evidence from self-report studies (Imperial/UW). Placebo effect substantial. Randomized controlled trials ongoing.
🌀
Meso-dose
5–15% full dose
Mildly psychoactive. Altered perception. "Museum dose." Less studied. Some clinicians use this range for trauma processing without full dissolution of ego. The therapeutic sweet spot for anxiety, creativity, and mild depression may be here.
✨
Full dose
20–35mg psilocybin
Full mystical experience. Ego dissolution possible. This is the dose used in the Johns Hopkins and NYU trials showing 70–80% remission in treatment-resistant depression. Not taken repeatedly, typically 1–3 sessions. The lasting change is structural, not chemical.
The honest microdosing picture: the science is genuinely mixed. Three randomized controlled trials (Szigeti 2021, Szigeti 2022, Szigeti et al. 2023 at Imperial College) found that microdosing effects were statistically indistinguishable from placebo when participants were properly blinded. However, this doesn't mean nothing is happening, it means the expectation effect is large, and the physiological effect at sub-perceptual doses may require better measurement tools.
What the data does show clearly: microdosing is generally safe, non-addictive, and non-toxic. Psilocybin has no known lethal dose in humans. There are no known cases of overdose death. The risk profile is excellent even if the efficacy data is still being established.
Verdict on Microdosing
Microdosing likely produces real effects in some people through some combination of placebo, habit formation, and sub-threshold pharmacology. It is not the cure for depression it's been marketed as. The therapeutic revolution in psychedelics is happening at full doses in clinical settings, not at microdoses. However: if someone reports feeling better and isn't harming themselves, the harm reduction calculus is favorable. The data doesn't condemn it, it just doesn't yet confirm the specific claims.
Section VI
The Non-Drug Pharmacopoeia: EMDR, Music, Art & Going Outside
The most underrated insight in modern neuroscience: experience changes the brain structurally. The same brain regions, the same receptor systems, the same downstream neuroplasticity that drugs target, they can also be accessed through movement, attention, music, beauty, and the natural world. These are not "soft" alternatives to medicine. They are medicine with a different delivery mechanism.
👁️
EMDR Therapy
Eye Movement Desensitization and Reprocessing
Bilateral stimulation (eye movements, tapping, sound) while the patient holds a traumatic memory activates both hemispheres simultaneously. The mechanism is not fully understood but the results are robust: EMDR consistently outperforms SSRIs for PTSD in randomized trials. The WHO and APA both recommend it as a first-line PTSD treatment. Current theory: the dual attention state during bilateral stimulation may mimic REM sleep, where memory consolidation and emotional processing naturally occur. The trauma is "moved" from vivid sensory memory to narrative autobiographical memory.
Strong evidence · PTSD
🎵
Music Therapy
Neurologic Music Therapy · Clinical & Informal
Music is processed across the entire brain, auditory cortex, motor cortex, limbic system, prefrontal cortex, cerebellum. It is the only known stimulus that activates all four lobes simultaneously. Music therapy has randomized trial evidence for: Alzheimer's cognition and agitation, depression, anxiety, pain management (reduces opioid requirements post-surgery by ~30%), Parkinson's gait (rhythm entrains motor circuits), stroke rehabilitation, NICU premature infant development, and autism social communication. The mechanism is partly dopaminergic (music triggers the same dopamine reward circuits as food and sex) and partly attentional (it captures and directs cognition).
Strong evidence · Multiple indications
🎨
Art Therapy
Visual Arts · Expression · Making
Creating visual art bypasses verbal processing, which is often the bottleneck in trauma therapy. Many traumatic memories are stored somatically and imagistically, not linguistically, they can't be "talked through" because language wasn't active when they were encoded. Making, drawing, painting, sculpting, accesses those encoded states through the same sensory channels. Studies show significant effects on PTSD symptom reduction, cancer-related distress, and pediatric anxiety. The act of making is also dose-able and repeatable in a way that talking isn't, and the product can be examined, modified, and discussed.
Emerging evidence · Trauma, anxiety
🌿
Ecotherapy / Nature Exposure
Shinrin-yoku · Awe · Restorative environments
Time in nature measurably reduces cortisol, blood pressure, heart rate, and amygdala activation. Japanese research on Shinrin-yoku (forest bathing) found significant immune enhancement via increased NK cell activity, persisting for 30 days after a 3-day forest stay. The mechanism involves phytoncides (antimicrobial compounds from trees), visual complexity that engages bottom-up attention restoration, and possibly the microbiome, soil bacteria Mycobacterium vaccae appears to stimulate serotonin production via the vagus nerve. The feeling of being small in a large landscape, awe, reliably reduces self-referential rumination.
Strong evidence · Depression, cortisol, immunity
🏃
Exercise as Antidepressant
BDNF · Neurogenesis · Endorphins
A 2023 Lancet meta-analysis of 1,039 randomized trials (the largest ever) found exercise reduces depression symptoms 1.5× more than SSRIs. The primary mechanism is BDNF (brain-derived neurotrophic factor), exercise is the most powerful known stimulator of this neural growth hormone, which promotes neurogenesis in the hippocampus (the brain region most damaged by chronic stress). Moderate aerobic exercise for 30 minutes 3× per week shows effects comparable to Zoloft in major depression. There are no side effects except cardiovascular health, musculoskeletal stress, and time cost.
Strongest evidence · Depression, anxiety
🧘
Contemplative Practice
Meditation · Breathwork · Yoga · Prayer
Structural MRI studies show long-term meditators have measurably thicker prefrontal cortices and smaller amygdalae. MBSR (Mindfulness-Based Stress Reduction) has strong RCT evidence for anxiety, depression, chronic pain, and immune function. The mechanism is attentional, practices that train sustained and flexible attention directly remodel the default mode network (the "resting" brain state that generates rumination). Breathwork (particularly coherent breathing at ~5.5 breaths/minute) activates the vagus nerve and measurably shifts the nervous system from sympathetic to parasympathetic. These are not soft skills. They are biological state changes.
Strong evidence · Anxiety, chronic pain
🤝
Social Connection
Oxytocin · Loneliness · Belonging
Loneliness is now classified by Vivek Murthy (US Surgeon General, 2023) as a public health epidemic. The mortality risk of chronic loneliness is equivalent to smoking 15 cigarettes a day, it raises all-cause mortality by 26%. Conversation, touch, shared meals, and eye contact trigger oxytocin release and down-regulate the threat response. There is strong evidence that the therapeutic alliance (the relationship between therapist and patient) predicts outcome across all forms of psychotherapy more reliably than the specific modality used. The mechanism is the relationship, not the technique.
Strong evidence · Mortality, depression
💊
Psychedelic-Assisted Therapy
MDMA · Psilocybin · Ketamine · Clinical
The synthesis: psychedelics don't work by themselves. The most effective models use the compound to catalyze therapy, to open a window of neuroplasticity and emotional access that allows therapeutic processing to occur faster and more deeply. MDMA + PTSD therapy: 67% no longer met PTSD criteria after 3 sessions (vs 32% for therapy alone). Psilocybin + psychotherapy: 70–80% meaningful reduction in treatment-resistant depression. The drug isn't the medicine. The drug + the set + the setting + the integration = the medicine.
Strong evidence · PTSD, depression
"Going outside is not a metaphor. The world is medicine. The mistake was thinking medicine only came in bottles."
Musica Universalis · The Pharmacopoeia
Section VII · Synthesis
The Underlying Truth
The pharmaceutical model treats the body as a broken machine needing specific spare parts. The integrative model treats the body as a dynamic system that, given the right inputs, knows how to heal. Both contain truth.
Antibiotics save lives that would have been lost. Insulin keeps diabetics alive. Antiretrovirals turned HIV from a death sentence to a manageable condition. These are triumphs of pharmaceutical chemistry with no natural equivalent at the necessary scale.
But for the epidemic conditions of the 21st century, depression, anxiety, chronic pain, addiction, PTSD, loneliness, the pharmaceutical model has significantly underperformed. SSRIs help roughly half of patients. Benzodiazepines treat symptoms while creating dependency. Opioids, prescribed at scale for pain, created the largest addiction epidemic in modern history. The drugs being suppressed, psilocybin, MDMA, ketamine, cannabis, showed better results, with lower addiction potential, in the trials that did run.
The common thread across EMDR, music therapy, nature exposure, meditation, and exercise is: they all increase neuroplasticity, reduce amygdala hyperactivity, and engage the prefrontal cortex. They work through the same downstream mechanisms as antidepressants, they just do it from the top down (experience → brain change) rather than bottom up (chemical → brain change).
The deepest truth is not that drugs are bad or good. It's that consciousness itself is chemical, and the ways to change it are more numerous and more natural than the pharmaceutical system had incentive to tell you. The river of healing runs through the forest, through music, through movement, through human touch, through carefully guided altered states, and yes, through some molecules discovered in 1943 or 10,000 BCE that have been waiting patiently in a Schedule I drawer for science to remember what it knew.
The Pythagorean Comma of Medicine
Just as the comma (δ = 0.013643) is the gap between where music theory predicts the octave should close and where it actually does, there is a gap in medicine between what we were told about healing and what the evidence actually shows. The comma doesn't invalidate music. It reveals that the system is richer than any single tuning can capture. The gap between pharmaceutical medicine and the full pharmacopoeia of human healing, plants, fungi, movement, music, connection, awe, is not a contradiction. It is the space where the real theory lives.
Timeline
From Willow Bark to Psilocybin Clinics
~3000 BCE
First Pharmacopoeias
Sumerian clay tablets list 250 plant drugs. Egyptian Ebers Papyrus (1550 BCE) describes 700 plant remedies. Cannabis listed in Chinese pharmacopoeia 2700 BCE. Opium poppy cultivated in lower Mesopotamia.
~2000 BCE – ongoing
Psychedelic Sacraments
Peyote use documented in Mesoamerica 5,700 years ago (oldest archaeological record). Psilocybe mushrooms in Mesoamerican iconography. Vedic soma (possibly Amanita muscaria). Eleusinian Mysteries possibly used ergot-derived psychedelic brew (kykeon). Ayahuasca use in Amazon, dating unknown but likely thousands of years.
1803
Morphine Isolated
Friedrich Sertürner isolates morphine from opium, the first time an active compound is extracted from a plant in pure form. Marks the beginning of modern pharmaceutical chemistry.
1897–1899
Aspirin & Heroin
Bayer synthesizes both aspirin (acetylsalicylic acid from willow bark) and heroin (diacetylmorphine from morphine) in the same year. Bayer marketed heroin as a non-addictive cough suppressant and morphine alternative. Both were sold over the counter.
1928
Penicillin Discovered
Alexander Fleming observes Penicillium mold killing bacteria. The mold had been producing penicillin for millions of years. Mass production begins 1943; saves millions of WWII soldiers and over 200 million lives since.
1943
LSD Synthesized & Discovered
Albert Hofmann accidentally absorbs LSD-25 through his fingertips on April 19, 1943 (now known as "Bicycle Day"). The first intentional psychedelic trip. LSD research begins immediately; over 1,000 papers published by 1965.
1955–1970
Golden Age of Psychedelic Research
Aldous Huxley publishes The Doors of Perception. Humphry Osmond coins "psychedelic." Harvard Psilocybin Project begins. LSD shows 50–90% abstinence in alcoholism trials. MAPS founders begin work. An entire clinical paradigm develops, then is destroyed by the CSA.
1970
The Great Suppression
Controlled Substances Act. LSD and psilocybin Schedule I. 25 years of near-total research halt. The War on Drugs begins. Cannabis, opioids, psychedelics all become political weapons. 50 million Americans arrested for drug offenses over the next five decades.
1994–2010
The Psychedelic Renaissance Begins
Rick Strassman publishes DMT research. Roland Griffiths begins psilocybin studies at Johns Hopkins. Robin Carhart-Harris leads Imperial College London research. Michael Pollan's How to Change Your Mind (2018) brings psychedelic science to mainstream awareness.
2017–present
FDA Breakthrough Designations & Legalization
MDMA for PTSD and psilocybin for depression both receive FDA Breakthrough Therapy status. Oregon legalizes therapeutic psilocybin (2020). Australia becomes first country to approve MDMA and psilocybin for clinical use (2023). The suppressed science is returning, with decades of human cost as the price of delay.